Yilong Wang
A5100439950- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Stroke Rehabilitation and Recovery
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Lipoproteins and Cardiovascular Health
- Intracerebral and Subarachnoid Hemorrhage Research
- Particle physics theoretical and experimental studies
- Neurological Disease Mechanisms and Treatments
- Intracranial Aneurysms: Treatment and Complications
- Quantum Chromodynamics and Particle Interactions
- High-Energy Particle Collisions Research
- Cardiovascular Health and Disease Prevention
- Blood Pressure and Hypertension Studies
- Cerebral Venous Sinus Thrombosis
- Peripheral Artery Disease Management
- Traumatic Brain Injury and Neurovascular Disturbances
- Neurological Disorders and Treatments
- Dementia and Cognitive Impairment Research
- Healthcare Systems and Practices
- Diabetes Treatment and Management
- Neuroinflammation and Neurodegeneration Mechanisms
- Diabetes, Cardiovascular Risks, and Lipoproteins
- S100 Proteins and Annexins
National Clinical Research Center for Digestive Diseases
2016-2025
Chinese Institute for Brain Research
2016-2025
Beijing Tian Tan Hospital
2016-2025
Capital Medical University
2016-2025
Sichuan University
2024-2025
West China Hospital of Sichuan University
2024-2025
The First Affiliated Hospital, Sun Yat-sen University
2025
Sun Yat-sen University
2025
University of Nottingham
2013-2024
University of California, San Francisco
2011-2024
Background: China bears the biggest stroke burden in world. However, little is known about current prevalence, incidence, and mortality of at national level, trend past 30 years. Methods: In 2013, a nationally representative door-to-door survey was conducted 155 urban rural centers 31 provinces China, totaling 480 687 adults aged ≥20 All survivors were considered as prevalent cases time (August 31, 2013). First-ever strokes that occurred during 1 year preceding point-prevalent incident...
Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than alone.In randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours onset of high-risk TIA to combination (clopidogrel an initial dose 300 mg, followed by 75 mg per day for 90 days, plus 21 days) placebo...
We aimed to establish the prevalence, characteristics, and outcomes of intracranial atherosclerosis (ICAS) in China by a large, prospective, multicenter study. evaluated 2864 consecutive patients who experienced an acute cerebral ischemia<7 days after symptom onset 22 Chinese hospitals. All underwent magnetic resonance angiography, with measurement diameter main arteries. ICAS was defined as ≥50% reduction on angiography. The prevalence 46.6% (1335 patients, including 261 coexisting...
The role of endovascular therapy for acute stroke with a large infarction has not been extensively studied in differing populations. Download PDF the Research Summary. We conducted multicenter, prospective, open-label, randomized trial China involving patients large-vessel occlusion anterior circulation and an Alberta Stroke Program Early Computed Tomography Score 3 to 5 (range, 0 10, lower values indicating larger infarction) or infarct-core volume 70 100 ml. Patients were randomly assigned...
Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated clopidogrel.To estimate clopidogrel-treated attack.Three major alleles (*2, *3, *17) were genotyped among 2933 Chinese from 73 sites who enrolled in Clopidogrel High-Risk Patients Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted January 2, 2010, to March 20, 2012.Patients acute treatment clopidogrel...
Background As a leading cause of severe disability and death, stroke places an enormous burden on the health care system in China. There are limited data pattern current medical practice quality delivery for patients at national level. Aim The nation-wide prospective registry, China National Stroke Registry, will be considered with regard to its design, progress, geographic coverage, hospital patient characteristics. Methods Between September 2007 August 2008, Registry recruited consecutive...
China faces the greatest challenge from stroke in world. According to results Global Burden of Disease Study 2019, there were 3.94 million new cases, 28.76 prevalent cases and 2.19 deaths due 2019. Furthermore, is also leading cause disability-adjusted life-year (DALY) China, number DALYs reached 45.9 Several recent large-scale epidemiological surveys have updated data on pre-existing conditions contributed stroke. The age-adjusted prevalence overweight among Chinese adults aged 18–69 years...
Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Stroke is the leading cause of mortality and disability in China. Precise aetiological classification, imaging biological markers may predict prognosis stroke. The Third China National Registry (CNSR-III), a nationwide registry ischaemic stroke or transient attack (TIA) based on aetiology, biology markers, will be considered to clarify pathogenesis prognostic factors stroke.Between August 2015 March 2018, CNSR-III recruited consecutive patients with TIA from 201 hospitals that cover 22...
Background— The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases 90-day risk stroke without increasing hemorrhage comparison alone, but provided insufficient data to establish whether benefit persisted over a longer period time beyond termination. We report 1-year follow-up outcomes this trial. Methods Results— was randomized, double-blind, placebo-controlled conducted at...
Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient attack (TIA). Uncertainties remained about the optimal duration of dual TIA.
<h3>Objective:</h3> We aimed to investigate whether the efficacy and safety of clopidogrel plus aspirin vs alone were consistent between patients with without intracranial arterial stenosis (ICAS), in Clopidogrel High-Risk Patients Acute Non-disabling Cerebrovascular Events (CHANCE) trial. <h3>Methods:</h3> assessed interaction treatment effects 2 antiplatelet therapies among ICAS, identified by magnetic resonance angiography (MRA) CHANCE (ClinicalTrials.gov identifier NCT00979589)....
In China, stroke is a major cause of mortality, and long-term physical cognitive impairment. To meet this challenge, the Ministry Health China Stroke Prevention Project Committee (CSPPC) was established in April 2011. This committee actively promotes prevention control China. With government financial support 838.4 million CNY, 8.352 people from 536 screening points 31 provinces have received follow-up over last seven years (2012–2018). 2016, CSPPC issued plan to establish centers. shorten...
Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects antioxidant anti-inflammatory in animal models. The present clinical trial aimed at testing the dexborneol versus on 90-day functional outcome patients acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III was conducted 48 hospitals China between May 2015 December...
Abstract Background Triglyceride-glucose (TyG) index was recently suggested to be a reliable surrogate marker of insulin resistance. We aim investigate the associations between baseline and long-term TyG with subsequent stroke its subtypes in community-based cohort. Methods A total 97,653 participants free history Kailuan Study were included. calculated as ln (fasting triglyceride [mg/dL] × fasting glucose [mg/dL]/2). Baseline measured during 2006–2007. Updated cumulative average used all...
DL-3-n-butylphthalide (NBP) is a drug for treating acute ischemic stroke and may play neuroprotective role by acting on multiple active targets. The efficacy of NBP in patients with receiving reperfusion therapy remains unknown. To assess the safety intravenous thrombolysis and/or endovascular treatment. This multicenter, double-blind, placebo-controlled, parallel randomized clinical trial was conducted 59 centers China 90-day follow-up. Of 1236 stroke, 1216 18 years older diagnosed National...
Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when is initiated early (≤24 hours) after an acute mild stroke. The effect clopidogrel plus administered within 72 hours onset cerebral ischemia from atherosclerosis not well studied.
Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase patients acute ischemic stroke unclear.
Previous randomized clinical trials did not demonstrate the superiority of endovascular stenting over aggressive medical management for patients with symptomatic intracranial atherosclerotic stenosis (sICAS). However, balloon angioplasty has been investigated in a trial.